๐๏ธ Verified NIH Record โข Updated 2025-11-11
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) (NCT06519097)
A Randomized, Placebo-Controlled Trial of Tocotrienol in the Prevention of Pancreatic Intraductal Papillary Mucinous Neoplasm Progression
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: H. Lee Moffitt Cancer Center and Research Institute
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with ฮด-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Who can join: Review the eligibility criteria below.
Location: Moffitt Cancer Center โ Tampa, Florida
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- Moffitt Cancer Center โ Tampa, Florida
- University of Nebraska Medical Center โ Omaha, Nebraska
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Neoplasm of Pancreas clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.